CLART CMA
CLART CMA is a method of molecular biology. The kit includes the reagents for amplification and detection/ identification of the most frequent mutations of oncogenes in the signaling pathway of EGFR.
The mutations that the kit detects/identifies are the following:
— KRAS:G12A, G12C, G12D, G12R, G12S, G12V, G13D, Q61H, Q61L
— BRAF: V600E, V600K
— PI3K: E542K, E545D, E545K, H1047R
The amplification product, which is the result of the polymerase chain reaction technique (PCR), is detected with the use of a new technological platform: CLART (Clinical Array Technology). The platform is based on low density micro-arrays placed at the bottom of the micro vial tube.
The kit detects 9 mutations of the Kras gene in codons 12,13 and 61, 2 mutations of the Bras gene in codon 600 and 4 mutations of the PI3K gene in codons 9 and 20 in paraffin embedded samples (FFPE, formalin fixed paraffin embedded). All amplification tubes include internal control of DNA extraction and confirmation of DNA extraction, as well as internal control to confirm DNA amplification of the sample.
CLART iKras – Nras
CLART CMA is a method of molecular biology. The kit includes the reagents for amplification and detection/ identification of the most frequent mutations of oncogene Nras in the signaling pathway of EGFR.
The mutations that the kit detects/identifies are the following:
— Nras: G12D, Q61H (183 A>T), Q61R, Q61K,Q61L, K117N (351 G<C), A146T
— Kras (infrequent): Q61H (183 A>C), K117N (351 A>C), K117N (351 A>T), A146V, A146T
Sample: colorectal biopsies
The kit detects 10 mutations associated to the answer on the treatment of patients with metastatic colorectal cancer.
The amplification product, which is the result of the polymerase chain reaction technique (PCR), is detected with the use of a new technological platform: CLART (Clinical Array Technology). The platform is based on low density microarrays placed at the bottom of the micro vial tube.
All amplification tubes include internal control of DNA extraction and confirmation of DNA extraction, as well as internal control to confirm DNA amplification of the sample.
CLART Kras – Braf – PI3K
CLART Kras – Braf – PI3K1 is a method of molecular biology. The kit includes the reagents for amplification and detection/ identification of the most frequent mutations of oncogenes in the signaling pathway of EGFR.
The mutations that the kit detects/identifies are the following:
— KRAS: G12A, G12C, G12D, G12R, G12S, G12V,G13D, Q61H, Q61L
— BRAF: V600E, V600K
— PI3K: E542K, E545D, E545K, H1047R
The amplification product, which is the result of the polymerase chain reaction technique (PCR), is detected with the use of a new technological platform: CLART (Clinical Array Technology). The platform is based on low density micro-arrays placed at the bottom of the micro vial tube.
The kit detects 9 mutations of the Kras gene in codons 12,13 and 61, 2 mutations of the Bras gene in codon 600 and 4 mutations of the PI3K gene in codons 9 and 20 in paraffin embedded samples (FFPE, formalin fixed paraffin embedded). All amplification tubes include internal control of DNA extraction and confirmation of DNA extraction, as well as internal control to confirm DNA amplification of the sample.
References:
1. CLART® CMA KRAS·BRAF·PI3K, DETECTION AND GENETIC IDENTIFICATION OF POINT MUTATIONS IN 3 OF THE GENES BELONGING TO THE EGFR PATHWAY ASSOCIATED TO COLORECTAL CANCER -KRAS, BRAF AND PI3K FOR IN VITRO DIAGNOSIS
CLART EGFR
CLART CMA is a method of molecular biology. The kit includes the reagent for the amplification and the detection/ identification of 40 point mutations associated to the response to treatment of patients with non small-cell lung cancer.
The mutations that the kit detects/identifies are the following:
— Exon18: G719A, G719C, G719s
— Exon19: Complex Deletions and Mutations *
— Exon20: S768T, T790M, 2319_2320insCAC, D770_N771insG, V769_D770insASV, V770_N771insSVD
— Exon21: L858R, L861Q
The amplification product, which is the result of the polymerase chain reaction technique (PCR), is detected with the use of a new technological platform: CLART (Clinical Array Technology). The platform is based on low density micro-arrays placed at the bottom of the micro vial tube.
All amplification tubes include internal control of DNA extraction and confirmation of DNA extraction, as well as internal control to confirm DNA amplification of the sample.
References:
1. CLART® CMA EGFR, DETECTION AND GENETIC IDENTIFICATION OF POINT MUTATIONS, INSERTIONS AND DELETIONS IN THE GENE EGFR PATHWAY ASSOCIATED TO NON SMALL CELL LUNG CANCER FOR IN VITRO DIAGNOSIS
Colorectal cancer
Colorectal cancer constitutes a major public health issue and it is one of the main causes of fatality by malignancies in the western world. It is the second most frequent tumor in the developed countries. It is known that Kras oncogene mutations are a negative predictive factor for response to anti-EGFR treatment on metastatic colorectal cancer. Braf detection is also important for the same reason.
CLART CMA test detects and, at the same time, identifies the mutations of Kras, Braf and PI3K oncogenes.
This test offers the necessary knowledge for the correct identification of patients with metastatic colorectal cancer that respond to anti-EGFR monoclone antibodies treatment.
It also helps to chose an individual focused treatment.
References
1.Εθνικό Σχέδιο Δράσης για τον Καρκίνο 2011-2015, Υπουργείο Υγείας http://www.anticancer.gov.gr/pages/52.National Institute for Health and Care Excellence Diagnostics consultation document KRAS mutation testing of tumours in adults with metastatic colorectal cancer, https://www.nice.org.uk/guidance/gid-dt14/documents/kras-mutation-testing-of-tumours-in-adults-with-metastatic-colorectal-cancer-diagnostics-consultation-document-pdf2
The information referred to for general information and informing the public and in any case can not replace a doctor or other suitably qualified health professional. The responsibility of the media carries by ENORASIS SA
